Joshua, Douglas

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Ludwig, H., Durie, B. G. M., Bolejack, V., Turesson, I., Kyle, R. A., Blade, J., Fonseca, R., Dimopoulos, M., Shimizu, K., San Miguel, J., et al. (2008) · Blood

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 230

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsNeutropenia and Cancer Infections

Cited by 212

A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma

Rajeev Krishnan, S., De Rubis, G., Suen, H., Joshua, D., Lam Kwan, Y., & Bebawy, M. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsExtracellular vesicles in disease

Cited by 34